CAS
PBYI icon

CTC Alternative Strategies’s Puma Biotechnology PBYI Stock Holding History

CTC Alternative Strategies’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,100
Closed -$64.1K – 248
2024
Q1 		$64.1K Buy
+12,100
New +$65.2K 0.04% 95

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CTC Alternative Strategies's PBYI Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 12,100 shares — an estimated $64.1K sold.

CTC Alternative Strategies first reported a position in PBYI in Q1 2024 and held it in 1 quarter. The position peaked at $64.1K in Q1 2024. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 12,100 Puma Biotechnology shares in Q2 2024, an estimated $64.1K.
  • CTC Alternative Strategies first reported a position in Puma Biotechnology in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Puma Biotechnology position peaked at $64.1K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.